SUMMARY: Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 321,910 new cases of female breast cancer will be diagnosed in 2026, and about 42,140 women will die of the disease, largely due to metastatic recurrence.
Breast cancer remains a biologically heterogeneous disease, with approximately 70% of tumors expressing estrogen receptors (ER) and/or progesterone receptors (PR). Among patients with metastatic disease, Hormone Receptor (HR)–positive, HER2-negative tumors represent the most common subtype. However, 15%–20% of primary breast cancers overexpress HER2, a historically aggressive phenotype. Notably, more than half of HER2-positive tumors also coexpress hormone receptors, creating a biologically distinct subgroup characterized by signaling interplay between the HER2 and estrogen receptor pathways.
For patients with HR-positive, HER2-positive metastatic breast cancer, the current first-line standard consists of induction chemotherapy combined with dual HER2 blockade (Trastuzumab-HERCEPTIN® and Pertuzumab-PERJETA®), followed by maintenance HER2-targeted therapy plus endocrine therapy. While this approach has significantly improved outcomes, resistance remains inevitable for most patients. Preclinical data have consistently demonstrated bidirectional crosstalk between HER2 and ER signaling, as well as persistent activation of the cyclin D1–CDK4/6 axis, which may drive resistance to both endocrine and HER2-directed therapies. These mechanistic insights provided the scientific rationale for evaluating triple pathway inhibition, simultaneous targeting of HER2, ER, and CDK4/6 in this population.
Biological Rationale for CDK4/6 Inhibition
Cyclin-Dependent Kinases 4 and 6 (CDK4/6) regulate orderly progression from the G1 to S phase of the cell cycle through phosphorylation of the retinoblastoma (RB) protein. Aberrant activation of this pathway is implicated in tumor proliferation and therapeutic resistance across multiple breast cancer subtypes, including HER2-positive disease.
Palbociclib (IBRANCE®), an oral selective CDK4/6 inhibitor, suppresses RB phosphorylation and arrests cell-cycle progression. Preclinical HER2-positive models have demonstrated that sustained cyclin D1–CDK4/6 activity contributes to resistance to HER2-targeted therapies, and dual inhibition of CDK4/6 and HER2 has shown synergistic antitumor effects. Early-phase clinical studies further suggested that combining CDK4/6 inhibition with HER2-directed and endocrine therapy was feasible and potentially additive in efficacy. These findings led to the Phase 3 PATINA trial.
The PATINA Trial: Study Design
PATINA was an open-label, randomized Phase 3 study evaluating whether adding Palbociclib to maintenance therapy could extend disease control in patients with HR-positive, HER2-positive metastatic breast cancer.
Eligibility and Treatment Approach
Patients were enrolled after completing 4 to 8 cycles of induction chemotherapy plus HER2-targeted therapy without disease progression. Key eligibility criteria included:
- HR positivity (≥1% nuclear staining by IHC)
- HER2 positivity (IHC 3+ or ISH amplification per ASCO/CAP guidelines)
- No prior systemic therapy for metastatic disease beyond induction
- A disease-free interval ≥6 months after prior adjuvant HER2 therapy
A total of 518 patients were randomized 1:1:
- Palbociclib arm (n=261): Maintenance HER2-targeted therapy + endocrine therapy + Palbociclib (125 mg orally, 21 days on/7 days off; dose reductions permitted)
- Standard arm (n=257): Maintenance HER2-targeted therapy + endocrine therapy
Baseline characteristics were balanced. The median age was 53.4 years; 99% were female; 61.8% were postmenopausal. Importantly, 54.4% had de novo metastatic disease. The Primary endpoint was investigator-assessed Progression-Free Survival (PFS). Secondary endpoints included Objective Response, clinical benefit, safety, and Overall Survival.
Efficacy Outcomes: A Meaningful Extension of Disease Control
At a median follow-up of 53.5 months, the addition of Palbociclib resulted in a statistically and clinically significant improvement in PFS. The median PFS was 44.3 months in the Palbociclib group and 29.1 months in the standard therapy group (HR=0.75; P=0.02). The estimated PFS rates favored the Palbociclib arm over standard therapy at all measured time points and was 84.9% versus 73.2% at 12 months, 65,2% versus 55.3% at 24 months, and 46.5% versus 38.3% at 48 months respectively.
The depth and durability of response were also enhanced:
- Confirmed response rate: 32.9% vs. 24.8%
- Complete response rate: 14.3% vs. 11.3%
- Median duration of confirmed response: 44.9 vs. 30.8 months
Importantly, when the induction phase is included, total first-line disease control in the Palbociclib arm extended beyond four years. Early mortality was uncommon, with 6-month Overall Survival exceeding 99% in both groups, reflecting favorable biology among patients who completed induction therapy.
The control arm’s median PFS of 29 months exceeded initial projections, likely reflecting mandated endocrine therapy use and the exclusion of patients who progressed during induction, factors that enriched the study population for more favorable disease biology.
Safety Profile
The safety findings were consistent with known toxicities of Palbociclib and HER2-targeted therapies. Neutropenia was the predominant toxicity and febrile neutropenia was rare. Grade 3 and Grade 4 adverse events were 79.7% and 10% in the Palbociclib group versus 30.6% and 3.6% in the standard therapy group.
Clinical Implications
The PATINA trial supports a paradigm shift in the maintenance setting for HR-positive, HER2-positive metastatic breast cancer. By targeting HER2, Estrogen Receptor signaling, and CDK4/6-mediated cell-cycle progression concurrently, this strategy addresses key resistance mechanisms.
Achieving a median PFS exceeding 44 months represents a meaningful advance in a disease subtype historically associated with aggressive biology. While antibody–drug conjugates and other potent HER2-directed agents remain appropriate for selected high-risk patients, this chemotherapy-sparing maintenance intensification strategy provides durable disease control in a substantial proportion of patients.
The open-label design and limited racial diversity are important considerations. Additional analyses evaluating patient-reported outcomes, biomarker correlates, and central nervous system outcomes are ongoing and may further refine patient selection.
Conclusion
The addition of Palbociclib to maintenance anti-HER2 and endocrine therapy significantly prolongs Progression-Free Survival in patients with HR-positive, HER2-positive advanced breast cancer, albeit with increased, but manageable, hematologic toxicity. Triple pathway inhibition targeting HER2, estrogen receptor, and CDK4/6 signaling may now represent a compelling first-line maintenance strategy capable of extending disease control beyond four years in appropriately selected patients.
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer. Metzger O, Mandrekar S, Goel S, et al. N Engl J Med 2026;394:451-462
